Recent reports suggest that LEDGF is dispensable for normal hematopoiesis but important for leukemogenesis; therefore, LEDGF is being considered as a potential drug target for MLL-r leukemias (Blokken et al., 2017; Ashkar et al., 2018). The gene discussed is KMT2A; the disease is leukemia.